AFC Gamma, Inc. Form 8-K Summary
Business context and reporting period
This Form 8-K reports corporate and financing actions associated with AFC Gamma, Inc.’s listing of its common stock on Nasdaq under the symbol AFCG. The earliest reported event date was March 19, 2021; the filing was signed March 23, 2021. The filing identifies the registrant as AFC Gamma, Inc., although the request metadata refers to Advanced Flower Capital Inc.
Key financial and capital markets information
- The company completed its initial public offering on March 23, 2021.
- The IPO consisted of 6,250,000 shares priced at $19.00 per share.
- Gross IPO proceeds were $118.8 million before underwriting discounts, commissions, and offering expenses, assuming no exercise of the underwriters’ option.
- The underwriters received a 30-day option to purchase up to an additional 937,500 shares at the IPO price, less discounts and commissions.
- The filing does not provide revenue, net income, cash flow, margins, debt, liquidity balances, or other operating financial metrics.
Material changes and corporate actions
- An amended and restated management agreement with AFC Management, LLC, dated January 14, 2021, became effective upon the Nasdaq listing on March 19, 2021.
- The company adopted amended and restated bylaws effective March 19, 2021, in connection with the Nasdaq listing.
- The management agreement and restated bylaws had been previously approved by the board and, where applicable, stockholders.
Guidance, outlook, risks, and unusual items
The filing provides no earnings guidance or detailed management outlook. Key transaction-related considerations include underwriting discounts and offering expenses, the potential exercise of the underwriters’ overallotment option, and the company’s ongoing obligations under the management agreement. The filing refers investors to the March 18, 2021 prospectus for additional details regarding the management agreement, capital stock, and related risks.
Important facts to verify
- Verify the timing distinction between the March 19 Nasdaq listing and the March 23 IPO completion and filing signature date.
- Confirm whether the underwriters exercised any portion of the 937,500-share option; this filing does not state that they did.
- Review the full amended and restated management agreement, including fees, termination provisions, and potential conflicts of interest.
- Review the prospectus for use of IPO proceeds, investment strategy, risk factors, and post-IPO liquidity.
- Confirm net IPO proceeds after underwriting discounts, commissions, and offering expenses, which are not provided here.